Belite Bio, Inc
BLTE
Rank in Stocks
#3102
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Share Price
$145.23
Market Cap
$5.85B
Change (1 day)
1.72%
Change (1 year)
65.58%
Country
US
Trade Belite Bio, Inc (BLTE)
Category
Healthcare
Number of shares outstanding for Belite Bio, Inc (BLTE)
Number of shares outstanding as of June 2026: 40.18M
According to Belite Bio, Inc latest financial reports and stock price the company's current number of shares outstanding is 40.18M. At the end of December 2023 the company had 26.59M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Belite Bio, Inc (BLTE) from 2020 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 40.18M | 31.58% |
| 2024 | 30.54M | 14.84% |
| 2023 | 26.59M | 33.12% |
| 2022 | 19.98M | -17.09% |
| 2021 | 24.10M | 161.73% |
| 2020 | 9.21M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 531.87% |
US
|
|
| 396.00M | 885.51% |
US
|
|
| 478.91M | 1,091.85% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 54.76% |
NL
|
